Immunai
Active

Immunology based personalized disease treatments

Analytics Data Drug Development
Artificial Intelligence Deep Learning Machine Learning

Business Overview

DESCRIPTION

Decoding the immune system to improve health.

Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes.

Cutting-edge biology coupled with machine-learning to unravel the immune system. We are curating the largest proprietary data-set of multi-omic, immune-centric analyses of peripheral tissues. Our advanced analytics and data-visualization interface allows researchers to comprehensively view and interrogate data, and derive novel conclusions on the underlying mechanisms of disease. With a comprehensive view of the immune system, clinicians are better equipped to personalize and optimize treatment choices for each patient, and maximize positive outcomes. Immunai’s mission is to transform immunology by pioneering single-cell technologies coupled with the most cutting-edge AI methods.

FOUNDED
January 2019
EMPLOYEES
30
BUSINESS MODEL
B2B
OFFERING TYPE
Software
FUNDING STAGE
Seed
TOTAL FUNDING
$20 Million
SECTORS
Analytics Data Drug Development Healthcare Immunology Personalized Treatment

Founders

Immunai
Luis Voloch
CTO
AI Expert
Immunai
Noam Solomon
CEO
AI Expert
Immunai
Danny Wells
Scientific Founder
Immunai
Ansuman Satpathy
Scientific Founder
Immunai
Dan Littman
Scientific Founder

Funding Rounds

Date Announced

Funding Round

Amount Raised

Investors

May 2020
Seed
$20 M

AI Technology Stack

AI EMPLOYEES
5
AI APPLICATION
Vertical AI
AI TYPES
Artificial Intelligence Deep Learning Machine Learning

CONTACT

New York City
United States
180 Varick St, 6th Fl, 10014
Tel Aviv
Israel